Type 1 diabetes (T1D) is associated with a sustantially increased risk of cardiovascular (CV) events and premature death. The effect of the microvascular disease (MD) burden, i.e., the cumulative burden of retinopathy, nephropathy and peripheral neuropathy on all-cause mortality was evaluated in 774 T1D (age 40.2±11.7; DD 19.4±12.2 years; HbA1c 7.8±1.2%) in a mean follow-up of 10.6±2.5 years. Distribution of MD was: no-MD: n. 425 (54.9%); MD1: 250 (32.3%); MD2: 75 (9.7%); MD3: 24 (3.1%). Distribution was unchanged after esclusion of 41 T1D (5.3%) with previous CV events (CV+; 57.0%, 32.2%, 8.5% and 2.3%, respectively). Compared to no-MD, MD1-3 groups showed an adverse CV risk profile with steeply increase in age, DD, BMI, WHR, BP, HbA1c, uric acid and EURODIAB PCS risk score for major vascular outcomes (p<0.0001); total and LDL cholesterol, and triglycerides (p<0.05). eGFR (CKD-EPI) decreased, albuminuria progressively increased (p<0.0001). Rate of CV events and that of EURODIAB score ≥20 increased with MD: 1.6%, 5.6%, 17.3%, and 29.2%; 4.0%, 14.4%, 41.3% and 79.2%, respectively (p<0.0001). Consistently, rate of subjects on BP-lowering agents, RAS-blockers, statins e anti-platelet drugs increased (p<0.0001). A total of 52 deaths occurred during the 8,184 person-years of follow-up (6.7%; 6.36 x1000 person-years). Death rate increased with MD: no-MD 1.9%; MD1 6.8% (HR: 3.75, 95% CI 1.62-8.69); MD2 14.7% (7.10, 2.85-17.67); MD3 66.7% (45.64, 19.50-106.79; K-M, p<0.0001). Death rate was unchanged after esclusion of 41 CV+: 1.9%, 6.4%, 12.9% and 64.7% (p<0.0001). After adjustment for age and sex, HRs were: MD1 2.61 (95% CI 1.11-6.14); MD2 3.42 (1.29-9.06); MD3 16.21 (6.20-42.35; p<0.0001). In fully adjusted model, HRs were: MD1 2.51 (95% CI 1.01-6.23); MD2 2.97 (1.07-8.25); MD3 9.68 (3.19-29.36; p=0.001), with independent effects for age (HR 1.06), uric acid (HR 1.37) and smoking history (HR 2.45). Thus, the cumulative burden of MD independently affects the risk of all-cause death in T1D.


M. Garofolo: None. R. Giannarelli: None. M. Aragona: None. D. Lucchesi: None. L. Giusti: None. V. Sancho-Bornez: None. G. Daniele: None. R. Miccoli: None. G. Penno: None. S. Del Prato: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, GlaxoSmithKline plc., Intarcia Therapeutics, Inc., Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Novo Nordisk A/S, Servier, Sanofi, Takeda Pharmaceuticals U.S.A., Inc.. Research Support; Self; Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., AstraZeneca. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals U.S.A., Inc.. Advisory Panel; Self; Janssen Biotech, Inc., Abbott.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.